Innate Sensing of Cell-Free DNA and the Interferon-Mediated Control of HIV In Vivo
无细胞 DNA 的先天感知和体内干扰素介导的 HIV 控制
基本信息
- 批准号:10620085
- 负责人:
- 金额:$ 29.09万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-04-01 至 2027-03-31
- 项目状态:未结题
- 来源:
- 关键词:AccelerationAdvanced DevelopmentAftercareAgingApoptosisBindingBiological MarkersCD4 Positive T LymphocytesCell DeathCellsCharacteristicsChronicCirculationClinicalClinical OncologyCollectionCytidine DeaminaseDNA PackagingDataDeath RateDimensionsDiseaseDisease remissionEnabling FactorsEvaluationExhibitsHIVHIV AntibodiesHIV InfectionsHuman bodyImmuneImmunologicsIndividualInflammationInflammatoryIntegration Host FactorsInterferon Type IInterferonsInterruptionKineticsLinkMacrophageMeasurementMeasuresMediatingMitochondrial DNAMolecularMorbidity - disease rateMutationNucleic AcidsPhenotypePlasmaPlasma CellsPredispositionRecrudescencesRecurrent diseaseRefractorySamplingSelection for TreatmentsSignal TransductionStudy SectionSystemTimeViralVirus Latencyantiretroviral therapyantiviral immunitycancer diagnosiscell free DNAcohortcytokinediagnostic strategydisorder riskexperienceextracellular vesiclesin vivointerestliquid biopsymethylomemitochondrial dysfunctionmonocytemortalitynext generation sequencingpharmacologicpreventprognostic significanceresponsetransmission processuptakeviral rebound
项目摘要
PROJECT SUMMARY
While the advent of antiretroviral therapy (ART) has dramatically reduced the morbidity and mortality
associated with HIV infection, a cure is not achieved due to the persistence of latently-infected cells during
treatment. Accumulating data suggest that HIV-infected individuals often experience persistent immune
dysregulation, chronic inflammation, and accelerated aging even in the setting of ART-mediated viral
suppression. These realities have created a pronounced interest in developing strategies to cure HIV infection.
Identifying the host molecular determinants of HIV persistence and rebound kinetics following cessation of
antiretroviral therapy (ART) will be critical in developing effective strategies to cure HIV infection. We recently
applied a comprehensive systems profiling approach to plasma samples from HIV-infected individuals who
underwent analytical treatment interruption (ATI), to identify circulating host factors that enable prediction of
HIV rebound kinetics following ART interruption, and serve as potential pharmacological targets to promote
durable virologic remission in the absence of ART. The host factor exhibiting the strongest statistical
association with HIV rebound timing following ART cessation was circulating cell-free DNA (cfDNA) in
plasma. Specifically, increased cfDNA abundance in plasma was associated with delayed time-to-rebound.
cfDNA, released into circulation during programmed cell death, has been exploited extensively in the realm of
clinical oncology (often termed “liquid biopsy”). However, cfDNA remains largely unexplored in the setting of
HIV infection. In this R01 proposal, we rigorously explore cfDNA as a biomarker of HIV disease states, and we
investigate the molecular and immunologic mechanisms linking cfDNA to viral expression and rebound.
Our central hypotheses are that 1) cfDNA reflects the death rate of HIV-infected cells in vivo; and 2)
cfDNA promotes an antiviral state in the host (e.g. induction of type I interferon response) which
prevents viral rebound. Our project features an investigative team with basic, translational, and clinical
expertise, and leverages large collections of clinical samples from well-characterized HIV-infected individuals.
In Aim 1, we will apply next-generation sequencing (NGS) approaches to plasma samples from HIV-infected
individuals to extend and enhance the prognostic significance of cfDNA as a biomarker of natural HIV control in
vivo. In Aim 2, we will evaluate how the uptake and sensing of cfDNA by HIV target cells impacts cell fate and
the reactivation and replication of HIV. In Aim 3, we will determine how HIV-associated mitochondrial
dysfunction leads to cfDNA extrusion and ultimately induces type I interferon responses that prevent HIV
rebound. Our project will advance the development and evaluation of HIV cure strategies.
项目摘要
抗逆转录病毒治疗(ART)的出现大大降低了发病率和死亡率,
与HIV感染相关,由于潜伏感染细胞在治疗期间的持续存在,
治疗越来越多的数据表明,艾滋病毒感染者经常经历持续的免疫反应,
即使在ART介导的病毒感染的情况下,
镇压这些现实使人们对制定治疗艾滋病毒感染的战略产生了明显的兴趣。
确定艾滋病毒持续存在的宿主分子决定因素和停药后的反弹动力学
抗逆转录病毒疗法(ART)将是制定有效的策略,治愈艾滋病毒感染的关键。我们最近
对来自HIV感染者的血浆样本应用了一种全面的系统分析方法,
接受分析治疗中断(ATI),以确定能够预测
HIV在ART中断后的反弹动力学,并作为潜在的药理学靶点,以促进
在没有抗逆转录病毒治疗的情况下,持久的病毒学缓解。
与ART停止后HIV反弹时间相关的是循环游离DNA(cfDNA),
等离子体具体地,血浆中cfDNA丰度增加与延迟的反弹时间相关。
在程序性细胞死亡期间释放到循环中的cfDNA已经在生物医学领域中被广泛利用。
临床肿瘤学(通常称为“液体活检”)。然而,cfDNA仍然在很大程度上未被探索的背景下,
艾滋病毒感染。在R 01提案中,我们严格探索cfDNA作为HIV疾病状态的生物标志物,
研究cfDNA与病毒表达和反弹的分子和免疫机制。
我们的中心假设是:1)cfDNA反映了体内HIV感染细胞的死亡率;以及2)
cfDNA促进宿主中的抗病毒状态(例如诱导I型干扰素应答),
防止病毒反弹我们的项目具有基础,翻译和临床研究团队
它利用了来自特征明确的艾滋病毒感染者的大量临床样本。
在目标1中,我们将应用下一代测序(NGS)方法对来自HIV感染者的血浆样本进行测序。
个体,以扩展和增强cfDNA作为自然HIV控制的生物标志物的预后意义,
vivo.在目标2中,我们将评估HIV靶细胞对cfDNA的摄取和感测如何影响细胞命运,
艾滋病毒的重新激活和复制。在目标3中,我们将确定HIV相关的线粒体
功能障碍导致cfDNA挤出并最终诱导I型干扰素应答,
反弹我们的项目将推动艾滋病毒治疗策略的开发和评估。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Satish Kumar Pillai其他文献
Satish Kumar Pillai的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Satish Kumar Pillai', 18)}}的其他基金
Innate Sensing of Cell-Free DNA and the Interferon-Mediated Control of HIV In Vivo
无细胞 DNA 的先天感知和体内干扰素介导的 HIV 控制
- 批准号:
10661305 - 财政年份:2022
- 资助金额:
$ 29.09万 - 项目类别:
Project 3: Identifying plasma biomarkers predicting time to HIV rebound after treatment interruption
项目 3:识别血浆生物标志物,预测治疗中断后 HIV 反弹的时间
- 批准号:
10223997 - 财政年份:2017
- 资助金额:
$ 29.09万 - 项目类别:
Effects of Cell-Intrinsic Immunity on Establishment and Reversal of HIV Latency
细胞内在免疫对 HIV 潜伏期建立和逆转的影响
- 批准号:
9354580 - 财政年份:2015
- 资助金额:
$ 29.09万 - 项目类别:
Effects of Cell-Intrinsic Immunity on Establishment and Reversal of HIV Latency
细胞内在免疫对 HIV 潜伏期建立和逆转的影响
- 批准号:
9134183 - 财政年份:2015
- 资助金额:
$ 29.09万 - 项目类别:
High throughput measurement of envelope gene diversity for an HIV incidence assay
用于 HIV 发病率测定的包膜基因多样性的高通量测量
- 批准号:
8720184 - 财政年份:2013
- 资助金额:
$ 29.09万 - 项目类别:
High throughput measurement of envelope gene diversity for an HIV incidence assay
用于 HIV 发病率测定的包膜基因多样性的高通量测量
- 批准号:
8466485 - 财政年份:2013
- 资助金额:
$ 29.09万 - 项目类别:
High throughput measurement of envelope gene diversity for an HIV incidence assay
用于 HIV 发病率测定的包膜基因多样性的高通量测量
- 批准号:
8717846 - 财政年份:2013
- 资助金额:
$ 29.09万 - 项目类别:
Characterization of the HIV-1 Latent Reservoir in CCR5-Delta 32 Heterozygotes
CCR5-Delta 32 杂合子中 HIV-1 潜伏库的表征
- 批准号:
8603539 - 财政年份:2013
- 资助金额:
$ 29.09万 - 项目类别:
相似海外基金
ADVANCED DEVELOPMENT OF LQ A LIPOSOME-BASED SAPONIN-CONTAINING ADJUVANT FOR USE IN PANSARBECOVIRUS VACCINES
用于 Pansarbecovirus 疫苗的 LQ A 脂质体含皂苷佐剂的先进开发
- 批准号:
10935820 - 财政年份:2023
- 资助金额:
$ 29.09万 - 项目类别:
ADVANCED DEVELOPMENT OF BBT-059 AS A RADIATION MEDICAL COUNTERMEASURE FOR DOSING UP TO 48H POST EXPOSURE"
BBT-059 的先进开发,作为辐射医学对策,可在暴露后 48 小时内进行给药”
- 批准号:
10932514 - 财政年份:2023
- 资助金额:
$ 29.09万 - 项目类别:
Advanced Development of a Combined Shigella-ETEC Vaccine
志贺氏菌-ETEC 联合疫苗的先进开发
- 批准号:
10704845 - 财政年份:2023
- 资助金额:
$ 29.09万 - 项目类别:
Advanced development of composite gene delivery and CAR engineering systems
复合基因递送和CAR工程系统的先进开发
- 批准号:
10709085 - 财政年份:2023
- 资助金额:
$ 29.09万 - 项目类别:
Advanced development and validation of an in vitro platform to phenotype brain metastatic tumor cells using artificial intelligence
使用人工智能对脑转移肿瘤细胞进行表型分析的体外平台的高级开发和验证
- 批准号:
10409385 - 财政年份:2022
- 资助金额:
$ 29.09万 - 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES
针对大流行和突发冠状病毒的疫苗的高级开发
- 批准号:
10710595 - 财政年份:2022
- 资助金额:
$ 29.09万 - 项目类别:
Advanced development and validation of an in vitro platform to phenotype brain metastatic tumor cells using artificial intelligence
使用人工智能对脑转移肿瘤细胞进行表型分析的体外平台的高级开发和验证
- 批准号:
10630975 - 财政年份:2022
- 资助金额:
$ 29.09万 - 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE CANDIDATE FOR STAPHYLOCOCCUS AUREUS INFECTION
金黄色葡萄球菌感染候选疫苗的高级开发
- 批准号:
10710588 - 财政年份:2022
- 资助金额:
$ 29.09万 - 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES
针对大流行和突发冠状病毒的疫苗的高级开发
- 批准号:
10788051 - 财政年份:2022
- 资助金额:
$ 29.09万 - 项目类别: